Live Breaking News & Updates on Translational Medicine Group Of The Mass

Stay updated with breaking news from Translational medicine group of the mass. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

New gene-based vaccine strategy receives grant from the Bill & Melinda Gates Foundation

New gene-based vaccine strategy receives grant from the Bill & Melinda Gates Foundation
The AAVCOVID vaccine program, a novel gene-based vaccine strategy that utilizes an adeno-associated virus (AAV) vector, was granted an award for up to $2.1 million from the Bill & Melinda Gates Foundation.
The grant will aid the effort to bring further preclinical validation to the AAV vaccine platform. An AAVCOVID vaccine candidate is set to enter clinical trials in 2021.
The AAVCOVID vaccine program was founded at Mass General Brigham at the outset of the pandemic.
Preliminary tests of the vaccines stability and potency at different temperatures revealed that AAVCOVID candidates remained potent and effective when stored at room temperature for up to one month. This room temperature stability and the fact AAVCOVID vaccines do not require cold-chain freezer storage, could enable this AAV-based platform to develop a vaccine for COVID-19 and other diseases for developing countrie ....

United States , University Of Pennsylvania , Wyc Grousbeck , Lukh Vandenberghe , Joanw Miller , Jamesm Wilson , Mason Freeman , Emilia Fazzalari , Emily Henderson , Professor Of Ophthalmology At Harvard Medical School , Grousbeck Gene Therapy Center At Massachusetts Eye , Melinda Gates Foundation , Professor Of Medicine At Harvard Medical School , Gene Therapy Program , Massachusetts Consortium For Pathogen Readiness , Translational Medicine Group Of The Mass , Department Of Ophthalmology , Melinda Gates , Mass General Brigham , Grousbeck Gene Therapy Center , Massachusetts Eye , Associate Professor , Harvard Medical , Mass Eye , Massachusetts General Hospital , Novartis Gene ,

AAVCOVID single-dose, room temperature-stable COVID-19 vaccine supported by new funding

E-Mail
The AAVCOVID vaccine program, a novel gene-based vaccine strategy that utilizes an adeno-associated virus (AAV) vector, was granted an award for up to $2.1 million from the Bill & Melinda Gates Foundation.
The grant will aid the effort to bring further preclinical validation to the AAV vaccine platform. An AAVCOVID vaccine candidate is set to enter clinical trials in 2021.
The AAVCOVID vaccine program was founded at Mass General Brigham at the outset of the pandemic.
Preliminary tests of the vaccines stability and potency at different temperatures revealed that AAVCOVID candidates remained potent and effective when stored at room temperature for up to one month. This room temperature stability and the fact AAVCOVID vaccines do not require cold-chain freezer storage, could enable this AAV-based platform to develop a vaccine for COVID-19 and other diseases for developing countries without the necessary cooling infrastructure some vaccines require. ....

United States , University Of Pennsylvania , Wyc Grousbeck , Lukh Vandenberghe , Joanw Miller , Jamesm Wilson , Mason Freeman , Emilia Fazzalari , Professor Of Ophthalmology At Harvard Medical School , Grousbeck Gene Therapy Center At Massachusetts Eye , Melinda Gates Foundation , Professor Of Medicine At Harvard Medical School , Gene Therapy Program , Massachusetts Consortium For Pathogen Readiness , Translational Medicine Group Of The Mass , Department Of Ophthalmology , Melinda Gates , Mass General Brigham , Grousbeck Gene Therapy Center , Massachusetts Eye , Associate Professor , Harvard Medical , Mass Eye , Massachusetts General Hospital , Novartis Gene , Translational Medicine Group ,